Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis

Biochemical and Biophysical Research Communications

Volumn 417, Issue 1, 2012, Pages 217-222

  Keller, Johannes ^a   Catala Lehnen, Philip ^a   Wintges, Kristofer ^a   Schulze, Jochen ^a   Bickert, Thomas ^a   Ito, Wulf ^b   Horst, Andrea Kristina ^a   Amling, Michael ^a   Schinke, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Bone remodeling; Cytokines; Osteoblasts; Osteoclasts; Osteoporosis

Indexed keywords

INTERLEUKIN 33;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASOPHIL; BONE MARROW; CONTROLLED STUDY; EOSINOPHIL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MORPHOMETRICS; MOUSE; NEUTROPHIL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; TRABECULAR BONE;

ANIMALS; COLLAGEN TYPE I; INTERLEUKINS; MICE; MICE, TRANSGENIC; OSTEOBLASTS; TRANSGENES;

MUS; MUS MUSCULUS;

EID: 84855795870     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.11.088     Document Type: Article

References (40)

1. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13:791-801.
2. Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
3. Seitz S., Priemel M., Zustin J., Beil F.T., Semler J., Minne H., Schinke T., Amling M. Paget's disease of bone: histologic analysis of 754 patients. J. Bone Miner. Res. 2009, 24:62-69.
4. Okamoto K., Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int. Immunopharmacol. 2011, 11:543-548.
5. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12:6243s-6249s.
6. Edwards J.R., Mundy G.R. Advances in osteoclast biology: old findings and new insights from mouse models. Nat. Rev. Rheumatol. 2011, 7:235-243.
7. Villa A., Guerrini M.M., Cassani B., Pangrazio A., Sobacchi C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif. Tissue Int. 2009, 84:1-12.
8. Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 2008, 473:139-146.
9. Whyte M.P. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann. NY Acad. Sci. 2006, 1068:143-164.
10. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
11. Dinarello C.A. IL-1: discoveries, controversies and future directions. Eur. J. Immunol. 2010, 40:599-606.
12. Sabatini M., Boyce B., Aufdemorte T., Bonewald L., Mundy G.R. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc. Natl. Acad. Sci. USA 1988, 85:5235-5239.
13. Zwerina J., Redlich K., Polzer K., Joosten L., Krönke G., Distler J., Hess A., Pundt N., Pap T., Hoffmann O., Gasser J., Scheinecker C., Smolen J.S., van den Berg W., Schett G. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. USA 2007, 104:11742-11747.
14. Polzer K., Joosten L., Gasser J., Distler J.H., Ruiz G., Baum W., Redlich K., Bobacz K., Smolen J.S., van den Berg W., Schett G., Zwerina J. Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 2010, 69:284-290.
15. Kornman K.S., Crane A., Wang H.Y., di Giovine F.S., Newman M.G., Pirk F.W., Wilson T.G., Higginbottom F.L., Duff G.W. The interleukin-1 genotype as a severity factor in adult periodontal disease. J. Clin. Periodontol. 1997, 24:72-77.
16. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El-Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
17. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M.J., Verbsky J. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 2009, 360:2438-2444.
18. Kalliolias G.D., Liossis S.N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin. Investig. Drugs 2008, 17:349-359.
19. Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J. Immunol. 1985, 135:2562-2568.
20. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
21. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7:429-442.
22. Horwood N.J., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., Dunn A.R., Martin T., Gillespie M.T. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 1998, 101:595-603.
23. Schulze J., Bickert T., Beil F.T., Zaiss M.M., Albers J., Wintges K., Streichert T., Klaetschke K., Keller J., Hissnauer T.N., Spiro A.S., Gessner A., Schett G., Amling M., McKenzie A.N., Horst A.K., Schinke T. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 2011, 26:704-717.
24. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987, 2:595-610.
25. Albers J., Schulze J., Beil F.T., Gebauer M., Baranowsky A., Keller J., Marshall R.P., Wintges K., Friedrich F.W., Priemel M., Schilling A.F., Rueger J.M., Cornils K., Fehse B., Streichert T., Sauter G., Jakob F., Insogna K.L., Pober B., Knobeloch K.P., Francke U., Amling M., Schinke T. Control of bone formation by the serpentine receptor Frizzled-9. J. Cell Biol. 2011, 192:1057-1072.
26. Schulze J., Seitz S., Saito H., Schneebauer M., Marshall R.P., Baranowsky A., Busse B., Schilling A.F., Friedrich F.W., Albers J., Spiro A.S., Zustin J., Streichert T., Ellwanger K., Niehrs C., Amling M., Baron R., Schinke T. Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS One 2010, 5:e10309.
27. Dacquin R., Starbuck M., Schinke T., Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev. Dyn. 2002, 224:245-251.
28. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
29. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 2007, 37:2779-2786.
30. Schneider E., Petit-Bertron A.F., Bricard R., Levasseur M., Ramadan A., Girard J.P., Herbelin A., Dy M. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J. Immunol. 2009, 183:3591-3597.
31. Pushparaj P.N., Tay H.K., H'ng S.C., Pitman N., Xu D., McKenzie A., Liew F.Y., Melendez A.J. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. USA 2009, 106:9773-9778.
32. Stolarski B., Kurowska-Stolarska M., Kewin P., Xu D., Liew F.Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 2010, 185:3472-3480.
33. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., Pitman N., Mirchandani A., Rana B., van Rooijen N., Shepherd M., McSharry C., McInnes I.B., Xu D., Liew F.Y. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009, 183:6469-6477.
34. Miller A.M. Role of IL-33 in inflammation and disease. J. Inflamm. (Lond.) 2011, 8:22.
35. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., Baker A.H., McInnes I.B., Liew F.Y. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205:339-346.
36. Smith D.E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin. Exp. Allergy 2010, 40:200-208.
37. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
38. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., Pitman N., Kurowska-Stolarska M., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 2008, 105:10913-10918.
39. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., Nambu A., Abe T., Kiyonari H., Matsumoto K., Sudo K., Okumura K., Saito H., Nakae S. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 2010, 107:18581-18586.
40. Zaiss M.M., Kurowska-Stolarska M., Böhm C., Gary R., Scholtysek C., Stolarski B., Reilly J., Kerr S., Millar N.L., Kamradt T., McInnes I.B., Fallon P.G., David J.P., Liew F.Y., Schett G. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J. Immunol. 2011, 186:6097-6105.